192 related articles for article (PubMed ID: 23327579)
1. Regulatory perspective on remaining challenges for utilization of pharmacogenomics-guided drug developments.
Otsubo Y; Ishiguro A; Uyama Y
Pharmacogenomics; 2013 Jan; 14(2):195-203. PubMed ID: 23327579
[TBL] [Abstract][Full Text] [Related]
2. [Current PMDA Activities for Use of Biomarkers in Drug Evaluation].
Ishiguro A
Yakugaku Zasshi; 2015; 135(5):681-4. PubMed ID: 25948301
[TBL] [Abstract][Full Text] [Related]
3. Challenges of biomarkers in drug discovery and development.
Goodsaid F
Expert Opin Drug Discov; 2012 Jun; 7(6):457-61. PubMed ID: 22471322
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives.
Prasad K; Breckenridge A
Drug Discov Today; 2011 Oct; 16(19-20):867-72. PubMed ID: 21920454
[TBL] [Abstract][Full Text] [Related]
5. Harmonization of rules in GLP and pharmacokinetic analysis: regulatory view.
Grabowski T; Marczak M; Muszynski M; Jaroszewski JJ
Bioanalysis; 2012 Feb; 4(4):417-30. PubMed ID: 22394142
[TBL] [Abstract][Full Text] [Related]
6. Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan.
Otsubo Y
Clin Ther; 2015 Aug; 37(8):1627-31. PubMed ID: 25963998
[TBL] [Abstract][Full Text] [Related]
7. Generating and weighing evidence in drug development and regulatory decision making: 5th US FDA-DIA workshop on pharmacogenomics.
Shaw PM; Zineh I
Pharmacogenomics; 2010 Dec; 11(12):1629-35. PubMed ID: 21142905
[TBL] [Abstract][Full Text] [Related]
8. Integration of pharmacogenetics and pharmacogenomics in drug development: implications for regulatory and medical decision making in pediatric diseases.
Piana C; Surh L; Furst-Recktenwald S; Iolascon A; Jacqz-Aigrain EM; Jonker I; Russo R; van Schaik RH; Wessels J; Della Pasqua OE
J Clin Pharmacol; 2012 May; 52(5):704-16. PubMed ID: 21566202
[TBL] [Abstract][Full Text] [Related]
9. Drug-diagnostic co-development: how to harness the value.
Blair ED; Blakemore JA
Drug Discov Today; 2011 Oct; 16(19-20):902-5. PubMed ID: 21888987
[TBL] [Abstract][Full Text] [Related]
10. Drug development in oncology: a regulatory perspective.
Augustus S
Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan.
Ishiguro A; Yagi S; Uyama Y
J Hum Genet; 2013 Jun; 58(6):313-6. PubMed ID: 23657427
[TBL] [Abstract][Full Text] [Related]
12. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
Philip R; Carrington L; Chan M
Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
[TBL] [Abstract][Full Text] [Related]
13. International Conference on Harmonisation; Guidance on E15 Pharmacogenomics Definitions and Sample Coding; Availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2008 Apr; 73(68):19074-6. PubMed ID: 18677821
[TBL] [Abstract][Full Text] [Related]
14. The biomarker is not the end.
Nohaile M
Drug Discov Today; 2011 Oct; 16(19-20):878-83. PubMed ID: 21888986
[TBL] [Abstract][Full Text] [Related]
15. Overcoming regulatory and economic challenges facing pharmacogenomics.
Cohen JP
N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
[TBL] [Abstract][Full Text] [Related]
16. Regulatory agency consideration of pharmacogenomics.
Pendergast MK
Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
[TBL] [Abstract][Full Text] [Related]
17. The challenges of immunogenicity in developing biosimilar products.
Wadhwa M; Thorpe R
IDrugs; 2009 Jul; 12(7):440-4. PubMed ID: 19579165
[TBL] [Abstract][Full Text] [Related]
18. Promises of biomarkers in drug development--a reality check.
Marrer E; Dieterle F
Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
[TBL] [Abstract][Full Text] [Related]
19. Improving clinical trial sampling for future research - an international approach: outcomes and next steps from the DIA future use sampling workshop 2011.
Warner AW; Bienfait KL; Bledsoe M; Burckart G; Flamion B; Knoppers B; Nelsen AJ; Rudman A; Sieffert NJ; Uyama Y
Pharmacogenomics; 2013 Jan; 14(1):103-12. PubMed ID: 23252952
[TBL] [Abstract][Full Text] [Related]
20. Enabling pharmacogenomic clinical trials through sampling.
Warner A; Nelsen A; Bhathena A; Fitzgerald K; Gilardi S; Kelso E; Knoppers B; McLeod HL; Nelson R; Uyama Y; Weisman J; Rudman A
Pharmacogenomics; 2010 Dec; 11(12):1649-54. PubMed ID: 21142907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
